Application of blood-based biomarkers of Alzheimer's disease in clinical practice: Recommendations from Taiwan Dementia Society
Journal
Journal of the Formosan Medical Association = Taiwan yi zhi
Journal Volume
123
Journal Issue
12
Start Page
1210
End Page
1217
ISSN
0929-6646
Date Issued
2024-12
Author(s)
Lin, Yen-Ju
Lin, Yung-Shuan
Hong, Wei-Pin
Kuan, Yi-Chun
Wu, Kuan-Yi
Hsu, Jung-Lung
Wang, Pei-Ning
Pai, Ming-Chyi
Chen, Cheng-Sheng
Fuh, Jong-Ling
Hu, Chaur-Jong
Abstract
Blood-based biomarkers (BBM) are potentially powerful tools that assist in the biological diagnosis of Alzheimer's disease (AD) in vivo with minimal invasiveness, relatively low cost, and good accessibility. This review summarizes current evidence for using BBMs in AD, focusing on amyloid, tau, and biomarkers for neurodegeneration. Blood-based phosphorylated tau and the Aβ42/Aβ40 ratio showed consistent concordance with brain pathology measured by CSF or PET in the research setting. In addition, glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) are neurodegenerative biomarkers that show the potential to assist in the differential diagnosis of AD. Other pathology-specific biomarkers, such as α-synuclein and TAR DNA-binding protein 43 (TDP-43), can potentially detect AD concurrent pathology. Based on current evidence, the working group from the Taiwan Dementia Society (TDS) achieved consensus recommendations on the appropriate use of BBMs for AD in clinical practice. BBMs may assist clinical diagnosis and prognosis in AD subjects with cognitive symptoms; however, the results should be interpreted by dementia specialists and combining biochemical, neuropsychological, and neuroimaging information. Further studies are needed to evaluate BBMs' real-world performance and potential impact on clinical decision-making.
Subjects
Alzheimer's disease
Blood-based biomarkers
Diagnosis
Prognosis
SDGs
Type
journal article